利伐沙班治疗肺栓塞患者的临床观察及相关护理干预

发布时间：2019-05-17 19:55

【摘要】：目的:观察利伐沙班治疗肺栓塞患者的疗效、安全性。方法:选取肺栓塞患者100例,按随机数字表法分为观察组和对照组,各50例。两组患者均采用护理干预进行康复治疗,并于尿激酶20 000 IU/(kg·h),ivgtt,2 h溶栓治疗。观察组患者给予利伐沙班15 mg,bid,连续治疗3周,3周后改为20 mg,qd。对照组患者给予低分子肝素钙1 mg/kg,bid,联合华法林钠5 mg,qd,联合给药≥5 d后,至国际标准化比值(INR)为2~3时,停用低分子肝素钙,单独口服华法林钠。两组疗程均为3个月。观察两组患者临床疗效及治疗前后氧分压(PaO_2)、二氧化碳分压(PaCO_2)、D-二聚体水平,并记录咳嗽、胸痛、呼吸困难等临床症状缓解情况及不良反应发生率。结果:观察组患者有效率(90.0%)显著高于对照组(74.0%),差异有统计学意义(P0.05)。治疗后,两组患者PaO_2、PaCO_2水平明显高于治疗前,D-二聚体水平明显低于治疗前,且观察组变化幅度明显大于对照组,差异有统计学意义(P0.05)。观察组患者咳嗽、胸痛、呼吸困难等临床症状缓解率明显高于对照组,差异有统计学意义(P0.05)。观察组患者不良反应发生率(12.0%)显著低于对照组(30.0%),差异有统计学意义(P0.05)。结论:利伐沙班辅以合理的护理干预能显著提高肺栓塞患者的临床疗效,且不良反应发生率低。
[Abstract]:Objective: to observe the efficacy and safety of rivashaban in the treatment of pulmonary embolism. Methods: 100 patients with pulmonary embolism were randomly divided into observation group (n = 50) and control group (n = 50). The patients in both groups were treated with nursing intervention and thrombolysis with urokinase 20 000 IU/ (kg 路h), ivgtt,2 h). The patients in the observation group were treated with rivasaban 15 mg,bid, for 3 weeks and changed to 20 mg,qd. after 3 weeks. The patients in the control group were given low molecular weight heparin calcium 1 mg/kg,bid, combined with warfarin sodium 5 mg,qd, for more than 5 days, and when the international standardized ratio (INR) was 2 鈮，

本文编号：2479366